Study identifier:ALXN2060-TAC-302
ClinicalTrials.gov identifier:NCT04622046
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Symptomatic Transthyretin Amyloid Cardiomyopathy
Phase 3
No
ALXN2060
All
25
Interventional
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Apr 2024 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Eidos Therapeutics
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: ALXN2060 Participants will receive ALXN2060. | - |